2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population
Ming‐Lung Yu(National Sun Yat-sen University), Wan‐Long Chuang(Kaohsiung Medical University), Chen‐Hua Liu(National Taiwan University Hospital), Chia‐Yen Dai(Kaohsiung Medical University), Tsung‐Hui Hu(National Sun Yat-sen University), Pei‐Jer Chen(National Taiwan University), Chung‐Feng Huang(Kaohsiung Medical University), Jia‐Horng Kao(National Taiwan University Hospital), Cheng‐Yuan Peng(China Medical University), Yi‐Hsiang Huang(First Hospital of Lanzhou University), Chun‐Jen Liu(National Taiwan University), Chun‐Yen Lin(Chang Gung University), Han‐Chieh Lin(Taipei Veterans General Hospital), Chao‐Hung Hung(Chang Gung University)
Cited by 85
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569